Latest developments and future directions in dengue vaccines
Open Access
- 15 October 2013
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Vaccines
- Vol. 2 (1), 3-9
- https://doi.org/10.1177/2051013613507862
Abstract
Dengue is a mosquito-borne disease which is currently an expanding global health problem. The disease is caused by four closely related viruses, the dengue virus. There are no specific dengue therapeutics and prevention is currently limited to vector control measures. Development of an effective tetravalent dengue vaccine would therefore represent a major advance in the control of the disease and is considered a high public health priority. While a licensed dengue vaccine is not yet available, the scope and intensity of dengue vaccine development has increased dramatically in the last decade. The uniqueness of the dengue viruses and the spectrum of disease resulting from infection have made dengue vaccine development difficult. Several vaccine candidates are currently being evaluated in clinical studies. The candidate currently at the most advanced clinical development stage, a live-attenuated tetravalent vaccine based on chimeric yellow fever dengue virus, has progressed to phase III efficacy studies. Several other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates, are at earlier stages of clinical development. Additional technological approaches, such as virus-vectored and virus-like particle-based vaccines, are under evaluation in preclinical studies.Keywords
This publication has 46 references indexed in Scilit:
- Current progress in dengue vaccinesJournal of Biomedical Science, 2013
- Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)PLoS Neglected Tropical Diseases, 2013
- Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing AntibodiesPLOS ONE, 2013
- Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in miceVaccine, 2013
- A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy AdultsThe American Journal of Tropical Medicine and Hygiene, 2013
- ADVASC—New regional initiative supporting transition from dengue vaccine to vaccination in Southeast AsiaVaccine, 2012
- From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccineVaccine, 2011
- Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunityVaccine, 2011
- Different Innate Signatures Induced in Human Monocyte-derived Dendritic Cells by Wild-Type Dengue 3 Virus, Attenuated but Reactogenic Dengue 3 Vaccine Virus, or Attenuated Nonreactogenic Dengue 1-4 Vaccine Virus StrainsThe Journal of Infectious Diseases, 2011
- Substitution of Wild‐Type Yellow Fever Asibi Sequences for 17D Vaccine Sequencesin ChimeriVax–Dengue 4 Does Not Enhance Infection ofAedes aegyptiMosquitoesThe Journal of Infectious Diseases, 2008